CardioFocus, a company specialising in ablation treatments for cardiac arrhythmias, has announced the acquisition of the Electrophysiology Technology division from Galvanize Therapeutics.
The acquisition includes the CENTAURI System, a pulsed electric field generator with CE marking, and the QuickShot catheter ablation system, which includes a large area focal catheter and is currently in the development phase.
The CENTAURI System, commercially available in the UK and the EU, is designed to disrupt the electrical signals in the heart that lead to atrial fibrillation. It utilises a unique waveform and is compatible with various existing focal ablation catheters and mapping systems.
CardioFocus expects the acquisition to boost its position within the medical device sector, offering a comprehensive suite of ablation technologies.
The company's portfolio now includes the HeartLight X3 catheter ablation technology and the HeartLight X4 pulsed field ablation balloon designed for single-shot pulmonary vein isolation, with human trials expected to commence in 2024.
Furthermore, the acquisition includes a significant portfolio of intellectual property. This encompasses a licence across multiple patent families related to pulsed electric field therapies, ownership of several patent families in electrophysiology and pulsed fields, and knowledge of the waveform and algorithms that are engineered to minimise microbubbles and muscle stimulation.
CardioFocus CEO Steve Ogilvie said: “We look forward to welcoming Centauri users in the EU and recognise the important contribution these clinicians have made to our understanding of focal pulse field ablation. Through this acquisition we will expand our presence in Europe and the UK while supporting and growing our global HeartLight X3 and Centauri customer bases.
“We are dedicated to improving patient outcomes and optimising clinical workflow. This acquisition strengthens our leadership position as we innovate the next generation of pulsed field technologies for both focal and true single shot ablation.”
The companies have not disclosed the financial terms of the deal.
